Genentech buys Regor’s CDK inhibitors in $850m deal - Yahoo …
WEB14 hours ago · One of Regor’s Phase Ia trials (NCT05304962) is investigating RGT-419B in 12 patients with HR+/HER2-negative advanced breast cancer who had previously undergone CDK4 treatment. Data showed that ...
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK …
WEBRegor’s most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, will be added to Roche’s pipeline. RGT-419B is a potent CDK4 inhibitor with increased activity on CDK2 ...
Regor to Sell Breast Cancer CDK Inhibitors to Roche Unit for …
WEB2 days ago · Sep 30, 2024 5:44am. By Ian Walker. Regor Pharmaceuticals (USA) said it is selling a portfolio of CDK inhibitors used to treat breast cancer to Roche Holding unit Genentech for an upfront payment ...
Regor Therapeutics Group
WEBRegor Therapeutics Group is a clinical-stage biotechnology company developing innovative and clinically differentiated medicines, with an in-house pipeline encompassing leading assets in oncology, metabolism and auto-immunity.
Genentech takes over Regor’s RGT-419B for US$850m upfront
WEB19 hours ago · Genentech, the US subsidiary of Swiss pharmaceutical giant Roche AG, has strengthened the company's breast cancer pipeline by pre-licensing the global commercialisation rights to Regor Therapeutics' RGT-419B for US$850m. With a definitive purchase agreement of Genentech to acquire Chinese Regor Therapeutics Group’s next-generation CDK 4/6 ...
Regor Announces Promising Safety And Single Agent Efficacy …
WEBDec 7, 2023 · Regor Therapeutics Group ("Regor"), a global innovator powered by cutting-edge drug discovery engine and differentiated clinical development pipeline, today announced the results from Phase 1A...
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor…
WEBSHANGHAI, Dec. 27, 2021 /PRNewswire/ -- On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to proceed...
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor…
WEBOn December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration to proceed with Regor's Phase 1 clinical development plans for RGT-419B.
Regor Therapeutics Group
WEBRegor Therapeutics Group will work closely with NVIDIA to integrate high performance computing technology into Regor's proprietary Artificial Intelligence innovation platform - rCARD TM - to accelerate the discovery and development of innovative drugs.
Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
WEB16 hours ago · Per the terms of the deal, Regor will receive an upfront cash payment of $850 million, along with additional milestone payments. Regor’s most advanced orally-administered CDK4/2 inhibitor in the clinic, RGT-419B, will be added to Roche’s pipeline. RGT-419B is a potent CDK4 inhibitor with increased activity on CDK2 addressing a …